var data={"title":"Pleural fluid eosinophilia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pleural fluid eosinophilia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/contributors\" class=\"contributor contributor_credentials\">John T Huggins, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/contributors\" class=\"contributor contributor_credentials\">Amit Chopra, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/contributors\" class=\"contributor contributor_credentials\">Bruce S Bochner, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/contributors\" class=\"contributor contributor_credentials\">V Courtney Broaddus, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleural fluid eosinophilia (PFE, also called eosinophilic pleural effusion) is defined as pleural fluid with a nucleated cell count containing more than 10 percent eosinophils [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/1-4\" class=\"abstract_t\">1-4</a>]. It is estimated that approximately 10 percent of exudative pleural effusions are eosinophilic [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2,3,5\" class=\"abstract_t\">2,3,5</a>].</p><p>The presence of PFE narrows the differential diagnosis of a pleural effusion. Establishing the cause is dependent upon careful analysis of the clinical presentation and the pleural fluid. The most common cause is air or blood in the pleural space.</p><p>The pathogenesis, etiology, and evaluation of eosinophilic pleural effusions will be reviewed here. The general analysis of pleural fluid and evaluation of systemic eosinophilia and pulmonary parenchymal eosinophilia are discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">&quot;Diagnostic evaluation of a pleural effusion in adults: Initial testing&quot;</a> and <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a> and <a href=\"topic.htm?path=causes-of-pulmonary-eosinophilia\" class=\"medical medical_review\">&quot;Causes of pulmonary eosinophilia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The development of pleural fluid eosinophilia (PFE) requires the recruitment of bone marrow-derived eosinophils, since eosinophils are not part of the normal cellular milieu of lung and pleural tissue [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/6\" class=\"abstract_t\">6</a>]. The mechanisms that lead to the recruitment of eosinophils to the pleural space have not been clearly elucidated.</p><p>The time course of the development of pleural fluid and peripheral blood eosinophilia in response to air or blood in the pleural space suggests that the specific mechanisms that trigger eosinophil accumulation may vary [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/6\" class=\"abstract_t\">6</a>]. PFE develops within hours after a spontaneous pneumothorax compared to within 10 to 14 days after the onset of a traumatic or hemorrhagic pleural effusion [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/6\" class=\"abstract_t\">6</a>]. In addition, pleural trauma and hemothorax, but not pneumothorax, are often associated with peripheral blood eosinophilia that develops days after PFE.</p><p>One hypothesis for the development of PFE is that stimulation of pleural mesothelial cells by nonspecific injury (eg, air, blood, or trauma) leads to the production of cytokines, chemokines, and adhesion molecules that orchestrate eosinophil recruitment [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/7,8\" class=\"abstract_t\">7,8</a>]. In general, the recruitment of eosinophils into tissues is dependent upon mediators, such as eotaxins (eotaxin-1 [CCL11], eotaxin-2 [CCL24], and eotaxin-3 [CCL26]), interleukin (IL)-3, IL-5, <span class=\"nowrap\">granulocyte/macrophage</span> stimulating factor (GM-CSF), and RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/9-11\" class=\"abstract_t\">9-11</a>].</p><p>These agents cause eosinophil proliferation and maturation in the bone marrow, migration into the circulation, adhesion to the endothelium, and migration across endothelial barriers into tissue. In addition, there must be an interaction between the endothelial cells and circulating eosinophils for migration of eosinophils into the pleural space. Vascular cell adhesion molecule (VCAM-1) and eosinophil very late activation antigen (VLA-4) mediate this important eosinophil-endothelial cell interaction. Soluble VCAM-1 is significantly increased in eosinophilic pleural effusions compared to noneosinophilic effusions and probably contributes to their pathogenesis [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Eosinophil survival in the pleural space is also thought to be mediated by cytokines, such as IL-3, IL-5, and GM-CSF [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/13,14\" class=\"abstract_t\">13,14</a>]. Eosinophil apoptosis can be inhibited for up to two weeks when eosinophils are incubated with these cytokines; in contrast, eosinophils undergo apoptosis within two days when these cytokines are absent [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The spectrum of diseases associated with pleural fluid eosinophilia (PFE) mirrors that of pleural effusions in general and is strongly affected by the diseases prevalent in the population [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2,3,16,17\" class=\"abstract_t\">2,3,16,17</a>]. Pleural irritation or trauma (eg, pneumothorax, hemothorax, thoracic surgery) and malignancy are common causes, but several other processes should be considered in the differential diagnosis (<a href=\"image.htm?imageKey=PULM%2F82213\" class=\"graphic graphic_table graphicRef82213 \">table 1</a>). Even after careful evaluation, the etiology of PFE may remain unknown, especially when compared to non-eosinophilic effusions. As an example, in a meta-analysis of 687 cases of PFE, the most common causes were malignancy (26 percent) followed by idiopathic (25 percent) and parapneumonic (13 percent). The likelihood of an idiopathic effusion was significantly higher in eosinophilic pleural effusion than in non-eosinophilic pleural effusion [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"#H14\" class=\"local\">'Idiopathic'</a> below.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Pleural trauma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleural irritation or trauma in the form of pneumothorax, hemothorax, thoracotomy, thoracoscopy, or repeated thoracentesis has been associated with pleural fluid eosinophilia in numerous case reports and case series [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2,16,18,19\" class=\"abstract_t\">2,16,18,19</a>]. As examples:</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Air in the pleural space</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In many case series, spontaneous pneumothorax is the most common cause of PFE [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16,18\" class=\"abstract_t\">16,18</a>]. An intense eosinophilic pleuritis follows air entry into the pleural space within hours. One study has reported a time-related rise in percentage of pleural effusion in patients with spontaneous pneumothorax [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/20\" class=\"abstract_t\">20</a>]. </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Blood in the pleural space</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast to the rapid development of PFE after spontaneous pneumothorax, PFE is delayed following hemothorax, typically appearing by the tenth day, with eosinophilia appearing in the peripheral blood days later [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/21,22\" class=\"abstract_t\">21,22</a>]. There is significant correlation between the number of red blood cells and the number of eosinophils in the pleural fluid [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/23\" class=\"abstract_t\">23</a>]. Bleeding into the pleural space may contribute to the development of PFE in the setting of thoracotomy, chest trauma, benign asbestos pleural effusion, and pulmonary infarction [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Nonspecific pleural effusions that develop within 30 days after cardiac surgery are typically hemorrhagic and often eosinophilic. They are more common when the pleura has been excised (eg, for internal mammary grafting). (See <a href=\"topic.htm?path=pleural-effusions-following-cardiac-surgery#H2\" class=\"medical medical_review\">&quot;Pleural effusions following cardiac surgery&quot;, section on 'Nonspecific pleural effusions'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Repeated thoracentesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Repeated thoracentesis has been suggested as a cause of PFE, but the available data are conflicting [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16,21,23,24\" class=\"abstract_t\">16,21,23,24</a>]. The percentage of eosinophils does not increase in successive thoracenteses [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16,23\" class=\"abstract_t\">16,23</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Asbestos</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Benign asbestos pleural effusions (BAPEs) typically develop in the first two decades following asbestos exposure. Approximately one-third of BAPEs have an increased percentage of pleural eosinophils, ranging up to 50 percent of the total nucleated cell count [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/25\" class=\"abstract_t\">25</a>]. BAPEs resolve spontaneously, usually within four to six weeks, although residual pleural thickening may persist indefinitely. (See <a href=\"topic.htm?path=asbestos-related-pleuropulmonary-disease#H2476637934\" class=\"medical medical_review\">&quot;Asbestos-related pleuropulmonary disease&quot;, section on 'Benign asbestos pleural effusion'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 25 drugs have been implicated in the development of PFE (<a href=\"image.htm?imageKey=PULM%2F72026\" class=\"graphic graphic_table graphicRef72026 \">table 2</a>) and other drugs likely have the potential to cause PFE. Symptoms of drug-induced PFE are nonspecific and include pleuritic chest pain, cough, dyspnea, and occasional fever. Concomitant blood eosinophilia has been described with valproic acid, <a href=\"topic.htm?path=nitrofurantoin-drug-information\" class=\"drug drug_general\">nitrofurantoin</a>, <a href=\"topic.htm?path=dantrolene-drug-information\" class=\"drug drug_general\">dantrolene</a>, <a href=\"topic.htm?path=gliclazide-united-states-not-available-drug-information\" class=\"drug drug_general\">gliclazide</a>, <a href=\"topic.htm?path=tizanidine-drug-information\" class=\"drug drug_general\">tizanidine</a>, <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>, and <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/26-34\" class=\"abstract_t\">26-34</a>].</p><p>The latency between the development of PFE from first drug exposure is typically several months, with a range from a few days to one to two years (eg, <a href=\"topic.htm?path=nitrofurantoin-drug-information\" class=\"drug drug_general\">nitrofurantoin</a>) or even 12 years (eg, <a href=\"topic.htm?path=dantrolene-drug-information\" class=\"drug drug_general\">dantrolene</a>) [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/6,26\" class=\"abstract_t\">6,26</a>]. Herbal preparations (eg, kampo) have also been implicated in PFE [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/35\" class=\"abstract_t\">35</a>].</p><p>Symptoms usually begin to improve within the first few days after drug discontinuation and the pleural effusion completely resolves over several months [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/26\" class=\"abstract_t\">26</a>]. Treatment with oral glucocorticoids has been reported to speed resolution in a few cases [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/34,36,37\" class=\"abstract_t\">34,36,37</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infections caused by bacteria, fungi, mycobacteria, parasites, and viruses can cause PFE [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/3,16,38-51\" class=\"abstract_t\">3,16,38-51</a>]. Eosinophils appear late in the course of a parapneumonic effusion, usually three weeks or more, and often after resolution of the pneumonia [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/38,52\" class=\"abstract_t\">38,52</a>]. An eosinophilic parapneumonic effusion is unlikely to progress to empyema [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=parapneumonic-effusion-and-empyema-in-adults\" class=\"medical medical_review\">&quot;Parapneumonic effusion and empyema in adults&quot;</a>.)</p><p>The development of PFE in the setting of tuberculosis is now considered rare. However, older reports from populations with an increased prevalence of tuberculosis found that tuberculosis was responsible for up to 40 percent of PFEs [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/39-41\" class=\"abstract_t\">39-41</a>]. (See <a href=\"topic.htm?path=tuberculous-pleural-effusion\" class=\"medical medical_review\">&quot;Tuberculous pleural effusion&quot;</a>.)</p><p>Paragonimiasis is the most common parasite associated with PFE and is endemic to southeast Asia [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/43,44\" class=\"abstract_t\">43,44</a>]. The pleural fluid characteristics of <em>Paragonimus</em> infection are low pH (&lt;7.10) and glucose less than 60 <span class=\"nowrap\">mg/dL</span> (3.3 <span class=\"nowrap\">mmol/L)</span>. Cytological examination of the pleural fluid may reveal the parasite. (See <a href=\"topic.htm?path=paragonimiasis\" class=\"medical medical_review\">&quot;Paragonimiasis&quot;</a>.)</p><p>Other parasitic infections associated with PFE include sparganosis, toxocariasis, cutaneous myiasis, loiasis, lymphatic filariasis, amebiasis, ascariasis, strongyloidiasis, echinococcosis, and dracunculiasis [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/44-50\" class=\"abstract_t\">44-50</a>]. These are discussed further in the appropriate topic reviews.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Malignancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prevalence of PFE is low in malignant pleural effusion, reported anywhere from 2.3 to 6.8 percent [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/1,54\" class=\"abstract_t\">1,54</a>]. However, the reported frequency of pleural malignancy in patients with PFE ranges from 6 to 40 percent [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2,3,16,55\" class=\"abstract_t\">2,3,16,55</a>]. Most importantly, malignancy is diagnosed as frequently in eosinophilic effusion as in noneosinophilic effusions [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2\" class=\"abstract_t\">2</a>]. The likelihood of pleural malignancy appears to be inversely related to the percentage of eosinophils in the pleural space [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16,17\" class=\"abstract_t\">16,17</a>] but there is no absolute eosinophil percentage that would exclude malignancy [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/3,17\" class=\"abstract_t\">3,17</a>] and presence of eosinophils (&ge;10 percent) cannot be considered an indicator of benignancy [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16,23\" class=\"abstract_t\">16,23</a>].</p><p>Among the malignancies associated with PFE, lung cancer is the most common [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/3,16\" class=\"abstract_t\">3,16</a>]. In a review of 153 pleural fluid samples demonstrating PFE, 47 were associated with malignancy and of these, 23 were lung cancer [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Further investigations, such as thoracic computed tomography and pleural biopsy, either closed or thoracoscopic, should be pursued when pleural fluid cytology is negative but the patient has risk factors for underlying malignancy (eg, heavy smoking for many years) [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Pulmonary embolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleural effusion accompanies pulmonary embolism in 30 to 50 percent of cases, and 18 percent of these effusions are eosinophilic [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/4,56,57\" class=\"abstract_t\">4,56,57</a>]. These effusions are typically small (less than one-third of the hemithorax), unilateral exudates. One-half to two-thirds are bloody, due to associated pulmonary infarction. Pleuritic chest pain is typically present in the setting of pulmonary embolism with effusion. (See <a href=\"topic.htm?path=clinical-presentation-evaluation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-acute-pulmonary-embolism\" class=\"medical medical_review\">&quot;Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Rare causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PFE has rarely been reported in association with chronic eosinophilic pneumonia, rheumatoid pleural effusion, and eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss) [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/14,58\" class=\"abstract_t\">14,58</a>]. (See <a href=\"topic.htm?path=chronic-eosinophilic-pneumonia\" class=\"medical medical_review\">&quot;Chronic eosinophilic pneumonia&quot;</a> and <a href=\"topic.htm?path=overview-of-lung-disease-associated-with-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Overview of lung disease associated with rheumatoid arthritis&quot;</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Idiopathic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PFE is idiopathic in 8 to 35 percent of patients [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2,4,15-18,41,59,60\" class=\"abstract_t\">2,4,15-18,41,59,60</a>]. The typical patient with idiopathic PFE is a middle-aged man with a small to moderate-sized unilateral pleural effusion [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/15\" class=\"abstract_t\">15</a>]. The prognosis is excellent in these patients, even when the effusion persists for months. At least some of these cases may be due to unidentified asbestos exposure, occult pulmonary embolism, viral infection, or a medication.</p><p>Because PFE is a diagnosis of exclusion, patients with PFE and no obvious cause should be monitored until the effusion resolves or a known cause becomes apparent.</p><p>The approach to a patient with a pleural effusion of undetermined etiology is discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-pleural-effusion-in-adults-additional-tests-for-undetermined-etiology\" class=\"medical medical_review\">&quot;Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most cases, the evaluation of pleural fluid eosinophilia (PFE) follows the evaluation protocol for pleural effusions. However, certain clinical features may help to determine the etiology. The routine evaluation of pleural effusions is discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">&quot;Diagnostic evaluation of a pleural effusion in adults: Initial testing&quot;</a> and <a href=\"topic.htm?path=diagnostic-evaluation-of-pleural-effusion-in-adults-additional-tests-for-undetermined-etiology\" class=\"medical medical_review\">&quot;Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">History</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Historical information that may help to identify the etiology of PFE includes the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A condition in the last 1 to 4 weeks that may have led to entry of air or blood into the pleural space</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>List of medications, dietary supplements (eg, L-tryptophan), herbal preparations, and vitamins (see <a href=\"#H9\" class=\"local\">'Drugs'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of exposure to asbestos (see <a href=\"#H8\" class=\"local\">'Asbestos'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors for lung cancer or history of malignancy (see <a href=\"#H11\" class=\"local\">'Malignancy'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of infection (eg, fever, sweats, or chills) or travel or residence in endemic areas of fungi (eg, <em>Coccidioides</em>), tuberculosis, or parasites (eg, <em>Paragonimus</em>, <em>Strongyloides</em>, <em>Dracuncula</em>) (see <a href=\"#H10\" class=\"local\">'Infections'</a> above)</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Physical examination findings are generally nonspecific, but evidence suggesting chest trauma or skin lesions suggestive of a fungus should be sought. (See <a href=\"#H4\" class=\"local\">'Pleural trauma'</a> above.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Laboratory analysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory analysis of peripheral blood is usually nonspecific in patients with PFE, since there is only a weak correlation between the eosinophil percentages in the peripheral blood and pleural fluid [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16\" class=\"abstract_t\">16</a>]. Serologic studies for antibodies to fungi and parasites (eg, <em>Coccidioides</em>, <em>Echinococcus</em>, <em>Schistosoma</em>, <em>Strongyloides</em>, <em>Trichinella spiralis</em>, <em>Wuchereria bancrofti</em>) may be helpful in patients with a history of travel to or residence in endemic areas.</p><p>In patients with other features to suggest rheumatoid arthritis or eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss), measurement of cyclic citrullinated peptide or antineutrophil cytoplasmic antibody (ANCA) titers may be helpful. (See <a href=\"topic.htm?path=overview-of-lung-disease-associated-with-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Overview of lung disease associated with rheumatoid arthritis&quot;</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Pleural fluid analysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PFE is defined as pleural fluid with a nucleated cell count containing more than 10 percent eosinophils [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/1-4\" class=\"abstract_t\">1-4</a>]. The specific percentage of eosinophils in pleural fluid does NOT help differentiate between the different causes of PFE. The likelihood of pleural malignancy appears to be inversely related to the percentage of eosinophils in the pleural space [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16\" class=\"abstract_t\">16</a>] but there is no absolute eosinophil percentage that would exclude malignancy [<a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Determination of whether the fluid is an exudate or transudate is helpful. A list of transudative and exudative causes of PFE is provided in the table (<a href=\"image.htm?imageKey=PULM%2F82213\" class=\"graphic graphic_table graphicRef82213 \">table 1</a>). The differentiation of transudates and exudates is discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">&quot;Diagnostic evaluation of a pleural effusion in adults: Initial testing&quot;</a>.)</p><p>Pleural fluid cultures for bacteria, fungi, and mycobacteria should be performed. Cytological analysis should include examination for malignant cells and parasites.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Undetermined etiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When the etiology of a pleural effusion with eosinophilia remains undetermined after the above studies, further evaluation will typically include computed tomographic scanning and pleural biopsy. These tests are discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-pleural-effusion-in-adults-additional-tests-for-undetermined-etiology\" class=\"medical medical_review\">&quot;Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology&quot;</a> and <a href=\"topic.htm?path=medical-thoracoscopy-pleuroscopy-diagnostic-and-therapeutic-applications\" class=\"medical medical_review\">&quot;Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications&quot;</a>.)</p><p>After a comprehensive evaluation, a minority of patients have no apparent cause and are considered to have idiopathic PFE. (See <a href=\"#H14\" class=\"local\">'Idiopathic'</a> above.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">TREATMENT AND MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of PFE varies with the cause and is discussed on the appropriate topic reviews. Because PFE is a diagnosis of exclusion, patients with PFE and no obvious cause should be monitored until the effusion resolves or a known cause becomes apparent.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleural fluid eosinophilia (PFE) is defined as pleural fluid with a nucleated cell count containing greater than 10 percent eosinophils. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung and pleural tissue do NOT normally harbor eosinophils. As a result, the development of PFE requires the recruitment of bone marrow derived eosinophils. Nonspecific injury (eg, air, blood, or trauma) may stimulate pleural mesothelial cells and lead to production of the cytokines, chemokines, and adhesion molecules that orchestrate eosinophil recruitment. (See <a href=\"#H2\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common causes of PFE are the entry of air or blood into the pleural space malignancy, and infection. Less common causes include drugs, asbestos, pulmonary thromboembolism, chronic eosinophilic pneumonia, eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss), and rheumatoid pleuritis. (See <a href=\"#H3\" class=\"local\">'Etiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approximately 25 drugs have been implicated in the development of PFE (<a href=\"image.htm?imageKey=PULM%2F72026\" class=\"graphic graphic_table graphicRef72026 \">table 2</a>). Concomitant peripheral blood eosinophilia is sometimes present. (See <a href=\"#H9\" class=\"local\">'Drugs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PFE is idiopathic in 8 to 35 percent of patients. Because PFE is a diagnosis of exclusion, patients with PFE and no obvious cause should be monitored until the effusion resolves or a known cause becomes apparent. (See <a href=\"#H14\" class=\"local\">'Idiopathic'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacterial (including parapneumonic effusions), fungal, mycobacterial, parasitic, and viral infections can cause PFE. (See <a href=\"#H10\" class=\"local\">'Infections'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The frequency of pleural malignancy in PFE is variable and ranges between 6 to 40 percent, depending on the prevalence of malignancy in the population studied. Among malignancies, lung cancer is the most common. (See <a href=\"#H11\" class=\"local\">'Malignancy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/1\" class=\"nounderline abstract_t\">Hirsch A, Ruffie P, Nebut M, et al. Pleural effusion: laboratory tests in 300 cases. Thorax 1979; 34:106.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/2\" class=\"nounderline abstract_t\">Rubins JB, Rubins HB. Etiology and prognostic significance of eosinophilic pleural effusions. A prospective study. Chest 1996; 110:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/3\" class=\"nounderline abstract_t\">Mart&iacute;nez-Garc&iacute;a MA, Cases-Viedma E, Cordero-Rodr&iacute;guez PJ, et al. Diagnostic utility of eosinophils in the pleural fluid. Eur Respir J 2000; 15:166.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/4\" class=\"nounderline abstract_t\">Kalomenidis I, Light RW. Eosinophilic pleural effusions. Curr Opin Pulm Med 2003; 9:254.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/5\" class=\"nounderline abstract_t\">Nash DR, Wallace RJ Jr. Immunoglobulin E and other immunoglobulins in patients with eosinophilic pleural effusions. J Lab Clin Med 1985; 106:512.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/6\" class=\"nounderline abstract_t\">Heidecker J, Kaplan A, Sahn SA. Pleural fluid and peripheral eosinophilia from hemothorax: hypothesis of the pathogenesis of EPE in hemothorax and pneumothorax. Am J Med Sci 2006; 332:148.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/7\" class=\"nounderline abstract_t\">Katayama H, Yokoyama A, Kohno N, et al. Production of eosinophilic chemokines by normal pleural mesothelial cells. Am J Respir Cell Mol Biol 2002; 26:398.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/8\" class=\"nounderline abstract_t\">Georas SN, Beck LA, Stellato C. What is eotaxin doing in the pleura? Insights into innate immunity from pleural mesothelial cells. Am J Respir Cell Mol Biol 2002; 26:384.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/9\" class=\"nounderline abstract_t\">Kariyawasam HH, Robinson DS. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med 2006; 27:117.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/10\" class=\"nounderline abstract_t\">De Smedt A, Vanderlinden E, Demanet C, et al. Characterisation of pleural inflammation occurring after primary spontaneous pneumothorax. Eur Respir J 2004; 23:896.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/11\" class=\"nounderline abstract_t\">Kalomenidis I, Stathopoulos GT, Barnette R, et al. Eotaxin-3 and interleukin-5 pleural fluid levels are associated with pleural fluid eosinophilia in post-coronary artery bypass grafting pleural effusions. Chest 2005; 127:2094.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/12\" class=\"nounderline abstract_t\">Rothenberg ME, Ownbey R, Mehlhop PD, et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996; 2:334.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/13\" class=\"nounderline abstract_t\">Kalomenidis I, Mohamed KH, Lane KB, et al. Pleural fluid levels of vascular cell adhesion molecule-1 are elevated in eosinophilic pleural effusions. Chest 2003; 124:159.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/14\" class=\"nounderline abstract_t\">Nakamura Y, Ozaki T, Kamei T, et al. Factors that stimulate the proliferation and survival of eosinophils in eosinophilic pleural effusion: relationship to granulocyte/macrophage colony-stimulating factor, interleukin-5, and interleukin-3. Am J Respir Cell Mol Biol 1993; 8:605.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/15\" class=\"nounderline abstract_t\">Kalomenidis I, Light RW. Pathogenesis of the eosinophilic pleural effusions. Curr Opin Pulm Med 2004; 10:289.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/16\" class=\"nounderline abstract_t\">Krenke R, Nasilowski J, Korczynski P, et al. Incidence and aetiology of eosinophilic pleural effusion. Eur Respir J 2009; 34:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/17\" class=\"nounderline abstract_t\">Oba Y, Abu-Salah T. The prevalence and diagnostic significance of eosinophilic pleural effusions: a meta-analysis and systematic review. Respiration 2012; 83:198.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/18\" class=\"nounderline abstract_t\">Adelman M, Albelda SM, Gottlieb J, Haponik EF. Diagnostic utility of pleural fluid eosinophilia. Am J Med 1984; 77:915.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/19\" class=\"nounderline abstract_t\">Wysenbeek AJ, Lahav M, Aelion JA, Kaufmann L. Eosinophilic pleural effusion: a review of 36 cases. Respiration 1985; 48:73.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/20\" class=\"nounderline abstract_t\">Smit HJ, van den Heuvel MM, Barbierato SB, et al. Analysis of pleural fluid in idiopathic spontaneous pneumothorax; correlation of eosinophil percentage with the duration of air in the pleural space. Respir Med 1999; 93:262.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/21\" class=\"nounderline abstract_t\">Mart&iacute;nez Garc&iacute;a MA, Cases Viedma E, Perpi&ntilde;&aacute; Tordera M, Sanchis-Ald&aacute;s JL. Repeated thoracentesis: an important risk factor for eosinophilic pleural effusion? Respiration 2003; 70:82.</a></li><li class=\"breakAll\">Spriggs AI, Boddington NM. The Cytology of Pleural Effusions, 2d ed, Grune and Stratton, New York 1968.</li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/23\" class=\"nounderline abstract_t\">Ferreiro L, San Jos&eacute; E, Gonz&aacute;lez-Barcala FJ, et al. Eosinophilic pleural effusion: incidence, etiology and prognostic significance. Arch Bronconeumol 2011; 47:504.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/24\" class=\"nounderline abstract_t\">Chung CL, Chen YC, Chang SC. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest 2003; 123:1188.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/25\" class=\"nounderline abstract_t\">Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 1982; 247:617.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/26\" class=\"nounderline abstract_t\">Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med 2004; 25:141.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/27\" class=\"nounderline abstract_t\">Behnia M, Dowdeswell I, Vakili S. Pleural fluid and serum eosinophilia: association with fluoxetine hydrochloride. South Med J 2000; 93:611.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/28\" class=\"nounderline abstract_t\">Kuwahara T, Hamada M, Inoue Y, et al. Warfarin-induced eosinophilic pleurisy. Intern Med 1995; 34:794.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/29\" class=\"nounderline abstract_t\">Kaufman J, O'Shaughnessy IM. Eosinophilic pleural effusion associated with valproic acid administration. South Med J 1995; 88:881.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/30\" class=\"nounderline abstract_t\">Bunker CB, Sheron N, Maurice PD, et al. Isotretinoin and eosinophilic pleural effusion. Lancet 1989; 1:435.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/31\" class=\"nounderline abstract_t\">Yoshida H, Hasegawa R, Hayashi H, Irie Y. Imidapril-induced eosinophilic pleurisy. Case report and review of the literature. Respiration 2005; 72:423.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/32\" class=\"nounderline abstract_t\">Gujral N, Friedenberg F, Friedenberg J, et al. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996; 41:624.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/33\" class=\"nounderline abstract_t\">Middleton KL, Santella R, Couser JI Jr. Eosinophilic pleuritis due to propylthiouracil. Chest 1993; 103:955.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/34\" class=\"nounderline abstract_t\">Strong DH, Westcott JY, Biller JA, et al. Eosinophilic &quot;empyema&quot; associated with crack cocaine use. Thorax 2003; 58:823.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/35\" class=\"nounderline abstract_t\">Yamawaki I, Katsura H, Taira M, et al. [Six patients with pneumonitis related to blended Chinese traditional medicines]. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/36\" class=\"nounderline abstract_t\">Sen N, Ermis H, Karatasli M, et al. Propylthiouracil-associated eosinophilic pleural effusion: a case report. Respiration 2007; 74:703.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/37\" class=\"nounderline abstract_t\">Felz MW, Haviland-Foley DJ. Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy. South Med J 2001; 94:502.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/38\" class=\"nounderline abstract_t\">Murphy PP, Richardson SG. Q fever pneumonia presenting as an eosinophilic pleural effusion. Thorax 1989; 44:228.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/39\" class=\"nounderline abstract_t\">Poppius H, Kokkola K. Diagnosis and differential diagnosis in tuberculous pleurisy. Scand J Respir Dis Suppl 1968; 63:105.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/40\" class=\"nounderline abstract_t\">Kokkola K, Valta R. Aetiology and findings in eosinophilic pleural effusion. Scand J Respir Dis Suppl 1974; 89:159.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/41\" class=\"nounderline abstract_t\">Kamel A, Chabbou A, el Gharbi B. [Eosinophilic pleural effusion]. Rev Pneumol Clin 1989; 45:118.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/42\" class=\"nounderline abstract_t\">Merchant M, Romero AO, Libke RD, Joseph J. Pleural effusion in hospitalized patients with Coccidioidomycosis. Respir Med 2008; 102:537.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/43\" class=\"nounderline abstract_t\">Johnson JR, Falk A, Iber C, Davies S. Paragonimiasis in the United States. A report of nine cases in Hmong immigrants. Chest 1982; 82:168.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/44\" class=\"nounderline abstract_t\">Johnson RJ, Johnson JR. Paragonimiasis in Indochinese refugees. Roentgenographic findings with clinical correlations. Am Rev Respir Dis 1983; 128:534.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/45\" class=\"nounderline abstract_t\">Klion AD, Eisenstein EM, Smirniotopoulos TT, et al. Pulmonary involvement in loiasis. Am Rev Respir Dis 1992; 145:961.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/46\" class=\"nounderline abstract_t\">Ishii H, Mukae H, Inoue Y, et al. A rare case of eosinophilic pleuritis due to sparganosis. Intern Med 2001; 40:783.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/47\" class=\"nounderline abstract_t\">Emad A. Exudative eosinophilic pleural effusion due to Strongyloides stercoralis in a diabetic man. South Med J 1999; 92:58.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/48\" class=\"nounderline abstract_t\">Jacobson ES. A case of secondary echinococcosis diagnosed by cytologic examination of pleural fluid and needle biopsy of pleura. Acta Cytol 1973; 17:76.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/49\" class=\"nounderline abstract_t\">Gupta K, Sehgal A, Puri MM, Sidhwa HK. Microfilariae in association with other diseases. A report of six cases. Acta Cytol 2002; 46:776.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/50\" class=\"nounderline abstract_t\">Gentilini M, Carme B, Smith M, et al. A case of eosinophilic pleurisy due to Dracunculus medinensis infection. Trans R Soc Trop Med Hyg 1978; 72:540.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/51\" class=\"nounderline abstract_t\">Crum NF, Lederman ER, Stafford CM, et al. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004; 83:149.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/52\" class=\"nounderline abstract_t\">MacMURRAY FG, KATZ S, ZIMMERMAN HJ. Pleural-fluid eosinophilia. N Engl J Med 1950; 243:330.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/53\" class=\"nounderline abstract_t\">Pettersson T, Riska H. Diagnostic value of total and differential leukocyte counts in pleural effusions. Acta Med Scand 1981; 210:129.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/54\" class=\"nounderline abstract_t\">Light RW, Erozan YS, Ball WC Jr. Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med 1973; 132:854.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/55\" class=\"nounderline abstract_t\">Kuhn M, Fitting JW, Leuenberger P. Probability of malignancy in pleural fluid eosinophilia. Chest 1989; 96:992.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/56\" class=\"nounderline abstract_t\">Bynum LJ, Wilson JE 3rd. Characteristics of pleural effusions associated with pulmonary embolism. Arch Intern Med 1976; 136:159.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/57\" class=\"nounderline abstract_t\">Romero Candeira S, Hern&aacute;ndez Blasco L, Soler MJ, et al. Biochemical and cytologic characteristics of pleural effusions secondary to pulmonary embolism. Chest 2002; 121:465.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/58\" class=\"nounderline abstract_t\">Boyer D, Vargas SO, Slattery D, et al. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics 2006; 118:e914.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/59\" class=\"nounderline abstract_t\">Bower G. Eosinophilic pleural effusion. A condition with multiple causes. Am Rev Respir Dis 1967; 95:746.</a></li><li><a href=\"https://www.uptodate.com/contents/pleural-fluid-eosinophilia/abstract/60\" class=\"nounderline abstract_t\">Veress JF, Koss LG, Schreiber K. Eosinophilic pleural effusions. Acta Cytol 1979; 23:40.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6704 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETIOLOGY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Pleural trauma</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- Air in the pleural space</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Blood in the pleural space</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Repeated thoracentesis</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">Asbestos</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Drugs</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Infections</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Malignancy</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Pulmonary embolism</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Rare causes</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Idiopathic</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">EVALUATION</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">History</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Physical examination</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Laboratory analysis</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Pleural fluid analysis</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Undetermined etiology</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">TREATMENT AND MONITORING</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/6704|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/82213\" class=\"graphic graphic_table\">- Causes pleural eosinophilia</a></li><li><a href=\"image.htm?imageKey=PULM/72026\" class=\"graphic graphic_table\">- Drug pleural eosinophilia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">Approach to the patient with unexplained eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=asbestos-related-pleuropulmonary-disease\" class=\"medical medical_review\">Asbestos-related pleuropulmonary disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-pulmonary-eosinophilia\" class=\"medical medical_review\">Causes of pulmonary eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-eosinophilic-pneumonia\" class=\"medical medical_review\">Chronic eosinophilic pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-evaluation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-acute-pulmonary-embolism\" class=\"medical medical_review\">Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">Diagnostic evaluation of a pleural effusion in adults: Initial testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-pleural-effusion-in-adults-additional-tests-for-undetermined-etiology\" class=\"medical medical_review\">Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-thoracoscopy-pleuroscopy-diagnostic-and-therapeutic-applications\" class=\"medical medical_review\">Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-lung-disease-associated-with-rheumatoid-arthritis\" class=\"medical medical_review\">Overview of lung disease associated with rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paragonimiasis\" class=\"medical medical_review\">Paragonimiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=parapneumonic-effusion-and-empyema-in-adults\" class=\"medical medical_review\">Parapneumonic effusion and empyema in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-effusions-following-cardiac-surgery\" class=\"medical medical_review\">Pleural effusions following cardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculous-pleural-effusion\" class=\"medical medical_review\">Tuberculous pleural effusion</a></li></ul></div></div>","javascript":null}